Conference abstractPublished 27 Oct 2014
Patenting of biosimilars in India and related issues
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The new decade has foreseen significant changes reinvigorating the market for biosimilars, opening the way for their accelerated growth in the years to come. This has been substantiated by the vibrant Indian pharmaceutical industry and its burgeoning market for biologics. The Indian jurisdiction has grown to play an important role in the field of biologics and its protection. Furthermore, the Indian guidelines draw a close resemblance between its counterparts in its doctrine of principles and approach. This underlying homogeneity of the guidelines in addition to the lack of market exclusivity makes India a potential market for biosimilars. This talk deals with the patenting of biosimilars in India and the formidable barriers encountered in the process. It also aims to explore the various patentability requirements associated thereof.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Vijay Kumar Makyam”
